CT1341 is a new intravenous anaesthetic which appears to have overcome the disadvantages of the earlier steroid. The formulation is a mixture of two closely related steroids with Cremophor EL and the optimum dose for induction is 50-60 (J/kg though much larger doses can be given without serious side effects. As the dose is increased the incidence of muscle movements, respiratory depression and hypotension rises. Duration of action is intermediate between that of the barbiturates and propanidid and postoperative sickness is rare.
The advent of propanidid and subsequent work on this agent (Horatz, Frey and Zindler, 1965; Doenicke et al., 1968) suggested that rapid and complete recovery from anaesthesia was more likely to follow the use of a non-barbiturate whose reversal depended on breakdown or excretion than the use of a barbiturate dependent mainly on redistribution. Recovery of consciousness and mental clarity is probably as rapid after propanidid as is ever desirable and this drug is unlikely to be surpassed for anaesthetics of short duration. However, anaesthesia with propanidid is accompanied by a high incidence of involuntary muscle movements and postoperative sickness and, like the barbiturates, injection of large doses in poor-risk patients leads to marked hypotension .
Hydroxydione, the first steroid anaesthetic, was introduced in 1955 by Laubach, P'an and Rudel but its slow onset of action and the high incidence of venous thrombosis (Robertson and Williams, 1961) led to its abandonment. Work on steroid anaesthetics has continued since then but only in the last few years have Glaxo Research Laboratories been able to prepare a rapidly acting solution (CT1341) which was of low toxicity and available in aqueous solution (Child et al., 1971) .
CT1341 is a mixture of two steroids, 3a-hydroxy-5a-pregnane-ll,20-dione (Steroid I) and 21-acetoxy-3a-hydroxy-5a-pregnane-ll,20-dione (Steroid II). Both are anaesthetic agents but the former has approximately twice the potency of the latter. Steroid n, however, greatly increases the solubility of Steroid I and the standard solution contains 9 mg of the Steroid I with 3 mg of Steroid II in each ml of 20 per cent Cremophor EL. Investigations in a wide variety of animal species (Child et al., 1971) have shown the mixture to be rapidly acting, of short duration and with few side effects. In particular it is free from irritant properties to veins or arteries. Preliminary work in man (Campbell et al., 1971) showed that it caused no severe cardiovascular effects in the clinical range of dosage and that recovery was rapid and uncomplicated.
The present study was designed to determine the optimum dose of CT1341 when used as an induction agent and to obtain a dose/toxicity curve over the range of doses likely to be used. A preliminary report of this work has already been published (Montgomery et al., 1971) .
METHOD
The method of investigation was identical to that used in studies carried out at this centre with other induction agents (Dundee, Moore and Nicholl, 1962) .
The patients were all undergoing minor gynaecological surgery. Premedication was standardized as atropine 0.6 mg intramuscularly 1 hour before anaesthesia. Induction was carried out by an intravenous injection of a predetermined dose of CT1341 and anaesthesia was maintained by 75 per cent nitrous oxide in oxygen. If deeper anaesthesia was required, as shown by patient movement, this was provided by giving supplemental intravenous doses of CT1341, usually of 100 microlitres. As stated previously, CT1341 is a mixture of two drugs and it was found convenient to refer to the dose of the drug in microlitres per kilogramme body weight ([j,l/kg) . Table I shows the number of patients studied in different dosage groups, with the average age, weight and duration of anaesthesia. As can be seen, the ages and weights at each dosage level are broadly comparable. There is some variation in the duration of operation, but as the study was primarily of induction characteristics, this was not considered to be important. Blood pressure was measured (using an oscillotonometer) before induction and at 1-minute intervals during anaesthesia. All patients were carefully observed during induction and anaesthesia for the occurrence of any side effects, such as involuntary muscle movements, coughing, hiccup and marked respiratory depression.
Each induction was carefully graded by the anaesthetist in one of four categories:
(1) Smooth, uncomplicated induction.
(2a) Induction with minor side effects not interfering with anaesthesia or surgery. (2b) Side effects which interfered with anaesthesia or surgery but did not endanger the patient's life. (3) Major side effects which could endanger the patient's life or make surgery impossible. Grades 1 and 2a were classed as acceptable; grades 2b and 3 were classed as unacceptable inductions.
On completion of surgery nitrous oxide was withdrawn and the patients were given 100 per cent oxygen for 1 minute. Two minutes after cessation of nitrous oxide the patients were observed and classified as "awake", "safe" or "unsafe". Patients were regarded as awake when they responded to questioning, e.g. opened eyes on command; safe was taken as return of protective pharyngeal reflexes and maintenance of a clear airway, and unsafe meant that the patient's airway needed support or that protective reflexes were still absent.
All patients were visited by the anaesthetist I hour and 6 hours following anaesthesia and asked about nausea and vomiting. The patients were also asked whether they recalled any dreams during the anaesthetic and if so whether the dreams were pleasant or unpleasant. Finally, they were asked if they found the anaesthetic pleasant or not and whether they would have the same anaesthetic again if the need arose.
RESULTS
All patients lost consciousness within one armbrain circulation when the dosage was adequate. However, 30 per cent of the patients receiving 25 l^l/kg and 20 per cent of those receiving 30 (jJ/kg failed to become unconscious. Above this dosage all patients were anaesthetized for a variable period. Table II shows that the incidence of excitatory side effects is strongly correlated with dose, the incidence rising from 5 to 75 per cent. Hiccup is less frequent and less closely correlated with dose. Respiratory depression prolonged enough to require ventilatory assistance only occurred with the 200 ^/kg dose.
The changes in arterial blood pressure are shown in figure 1. In the dose range 25-70 (J/kg falls of pressure were mainly in the 0-20 mm Hg range though the incidence of significant hypotension did increase with the dose. Even with the highest dose studied there were no instances of severe hypotension (60 mm Hg or more). The incidence of undesirable induction characteristics, together with failure to be anaesthetized have been taken into account in table III and figure 2. The table shows that the optimum dose is 50-60 (J.l/kg and in this range almost threequarters of all cases have completely smooth in- The recovery after CT1341 can be assessed by the percentage of patients classified as awake, safe and unsafe, after differing total doses of CT1341. The largest number awake after 2 minutes occurred in the 40-60 (d/kg dose range and as the total dose rose the degree of recovery at the 2-minute stage diminished (table IV) . Table V shows a comparison of the induction characteristics of CT134i with those of thiopentone, methohexitone and propanidid after atropine premedication. Excitatory effects occur more frequently than after comparable doses of thiopentone but less frequently than after methohexitone. As with thiopentone and propanidid, the incidence of respiratory upset is low following induction with CT1341 and this contrasts markedly with the effects of methohexitone. The occurrence of hypotension with CT1341 is similar to that with other agents. The rapid recovery after CT1341 is illustrated here also, where it is seen to compare favourably with propanidid when used in a similar manner.
The relative frequency of postoperative nausea and vomiting is illustrated in figure 3 . CT134I was preferable to the other induction agents in this respect, in similar groups of patients under- going minor gynaecological operations. Anaesthesia with CT1341 was followed by remarkably little nausea (7 per cent) or vomiting (5 per cent). The patient acceptance of CT1341 anaesthesia was high, as shown in table VI. Over 90 per cent of patients liked anaesthesia with this agent, which was slightly higher than the acceptance after methohexitone and distinctly better than after ketamine in similar series. Comparable figures for recall of dreams during anaesthesia are not available for methohexitone but 14 per cent recalled dreams after CT1341 anaesthesia compared with 62 per cent after ketamine. Only 6 per cent reported unpleasant dreams after CT1341. 
DISCUSSION
The new steroid anaesthetic CT1341 appears to be a satisfactory induction agent in the dose range 40-100 (J/kg. Induction is rapid with only minor excitatory effects and hypotension; it behaves like most other intravenous anaesthetics when given in optimum dosage which appears to be 50-60 [J/kg. Recovery, however, does seem to be more rapid than after the barbiturates, without the emetic sequelae which rnar recovery after propanidid. The euphoria descibed by Campbell et al. (1971) was not noted in the present series but certainly patients found the anaesthesia pleasant s as shown by the high acceptance rate. Below the ideal dose range induction of anaesthesia is often unpredictable and above this range side effects become more frequent and severe. On the other hand, the safety margin is high and even severe muscle movements are not life-threatening compared with the hypotension found with certain other induction agents in high dosage . The involuntary muscle movements found with CT1341 occurred soon after its injection and usually subsided spontaneously. There was no indication that administration of a further dose counteracted these movements. Certainly the suggestion of Campbell et al. (1971) that 150 pJ/kg was a more suitable dose in fit patients does not agree with the present experience. It seems likely that these involuntary muscle movements are directly related to dose, rate of injection and premedication, though the relevance of the two latter factors has still to be investigated. Esta formulacion es una mezcla de dos esteroides estrechamente reladonados y Cremophor EL, siendo la dosis Optima para la induccidn 50-60 /d/kg, aunque dosis mucho mas eleyadas pueden ser administradas sin efectos secundarios graves. A medida que es incrementada la dosis, aumenta la frecuencia de movimientos musculares, depresi6n respiratoria e hipotension. La duraci6n de la accidn es intermedia entre la de los barbituricos y la del propanidid y la enfermedad posopcratoria es rara.
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